Showing papers by "Jackson T. Wright published in 2006"
Case Western Reserve University1, University of Texas Health Science Center at Houston2, National Institutes of Health3, Tulane University4, Kaiser Permanente5, University of Minnesota6, Lehigh University7, Wright State University8, University of Missouri–Kansas City9, Veterans Health Administration10
TL;DR: It was found that coronary heart disease was much more common than end-stage renal disease in hypertensive patients with moderate to severe reductions in GFR who were followed for 6 years, and lower baseline GFR was associated with higher risk for CHD independent of other risk factors.
Abstract: In this post hoc analysis of a subgroup of the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), patients with hypertension and chronic kidney disease were more...
209 citations
University of Ottawa1, National Institutes of Health2, Rush University Medical Center3, Veterans Health Administration4, University of Texas Health Science Center at Houston5, Yeshiva University6, Rutgers University7, Marshfield Clinic8, University of Southern California9, University of Oklahoma10, Tulane University11, Case Western Reserve University12
TL;DR: In hypertensive patients, the risks for coronary events are similar, but for stroke, combined CVD, gastrointestinal bleeding, and angioedema are higher and for heart failure are lower for lisinopril-based compared with amlodipine-based therapy.
Abstract: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) provides a unique opportunity to compare the long-term relative safety and efficacy of angiotensin-convertin...
155 citations
TL;DR: This analysis identifies unique and potentially modifiable CV risk factors in this high-risk cohort and determined baseline factors that predict CV outcomes.
145 citations
TL;DR: Ramipril treatment was associated with a significantly lower risk of DM in African Americans with hypertensive kidney disease than amlodipine or metoprolol treatment.
Abstract: Background The African American Study of Kidney Disease and Hypertension was a multicenter trial of African Americans with hypertensive kidney disease randomized to an angiotensin-converting enzyme inhibitor (ramipril), a β-blocker (metoprolol succinate), or a calcium channel blocker (amlodipine besylate). We compared the incidence of type 2 diabetes mellitus (DM) and the composite outcome of impaired fasting glucose or DM (IFG/DM) for the African American Study of Kidney Disease and Hypertension interventions. Methods Cox regression models were used to evaluate (post hoc) the association of the randomized interventions and the relative risk (RR) of DM and IFG/DM and to assess the RR of DM and IFG/DM by several prerandomization characteristics. Results Among 1017 participants, 147 (14.5%) developed DM; 333 (42.9%) of 776 participants developed IFG/DM. Respective DM event rates were 2.8%, 4.4%, and 4.5% per patient-year in the ramipril-, amlodipine-, and metoprolol-treated groups. The RRs of DM with ramipril treatment were 0.53 ( P = .001) compared with metoprolol treatment and 0.49 ( P = .003) compared with amlodipine treatment. Respective IFG/DM event rates were 11.3%, 13.3%, and 15.8% per patient-year in the ramipril-, amlodipine-, and metoprolol-treated groups. The RRs of IFG/DM with ramipril treatment were 0.64 ( P P = .09) compared with amlodipine treatment. The RRs of DM and IFG/DM with amlodipine treatment compared with metoprolol treatment were 1.07 ( P = .76) and 0.84 ( P = .26), respectively. Conclusion Ramipril treatment was associated with a significantly lower risk of DM in African Americans with hypertensive kidney disease than amlodipine or metoprolol treatment.
38 citations